NCT01824576

Brief Summary

The purpose of the study is to evaluate the physiological response to application of the Intrathoracic Pressure Regulator (ITPR) in patients with compromised cerebral circulation. The study will evaluate the physiological response to intrathoracic pressure regulation (IPR) therapy in hemodynamically stable patients with compromised cerebral circulation who are on ventilatory support.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 29, 2013

Completed
3 days until next milestone

Study Start

First participant enrolled

April 1, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 5, 2013

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
11 months until next milestone

Results Posted

Study results publicly available

September 27, 2017

Completed
Last Updated

September 27, 2017

Status Verified

August 1, 2017

Enrollment Period

3.6 years

First QC Date

March 29, 2013

Results QC Date

July 6, 2017

Last Update Submit

August 30, 2017

Conditions

Keywords

ITPRCPPTBItraumatic brain injurycerebral perfusion pressureintrathoracic pressure regulator

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline in Cerebral Perfusion Pressure (CPP)

    Change from average baseline CPP compared with the average CPP during use of the ITPR.

    During 120 minutes of device use

Secondary Outcomes (8)

  • Change From Baseline in Systolic Blood Pressure (SBP)

    baseline to15 minutes following device use

  • Change From Baseline in PaCO2

    baseline and 15 minutes after device activation

  • Change From Baseline in Diastolic Blood Pressure (DBP)

    baseline to 15 minutes following device use

  • Change From Baseline in Mean Arterial Pressure (MAP)

    baseline to 15 minutes following device use

  • Change From Baseline in Heart Rate (HR)

    baseline to 15 minutes following device use

  • +3 more secondary outcomes

Study Arms (1)

ITPR

EXPERIMENTAL

Use of the ITPR for 120 minutes.

Device: ITPR

Interventions

ITPRDEVICE

Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.

Also known as: Intrathoracic Pressure Regulator, CirQlator
ITPR

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥18 years of age
  • intubated and mechanically ventilated on a volume controlled mode
  • head injury or other intracranial pathology and compromised cerebral perfusion
  • arterial line in place or alternative with continuous pressure monitoring
  • SpO2 ≥90%
  • mean arterial pressure \>55
  • admission to ICU or about to undergo neurosurgery with planned placement of an invasive intracranial pressure monitor
  • prior written informed consent

You may not qualify if:

  • cardiac or pulmonary injury
  • confirmed pneumothorax or hemothorax
  • serious neck injury resulting in neck swelling with jugular venous compression
  • evidence of ongoing uncontrolled bleeding
  • respiratory disease such as COPD, interstitial lung disease, or other parenchymal or pulmonary vascular disease
  • marked hypertension at time of device use defined as systolic blood pressure \>180 mmHg
  • congestive heart failure
  • women with positive serum or urine pregnancy test or breast feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Denver

Denver, Colorado, United States

Location

Baltimore

Baltimore, Maryland, United States

Location

MeSH Terms

Conditions

Craniocerebral TraumaBrain Injuries, Traumatic

Condition Hierarchy (Ancestors)

Trauma, Nervous SystemNervous System DiseasesWounds and InjuriesBrain InjuriesBrain DiseasesCentral Nervous System Diseases

Results Point of Contact

Title
Sr. Clinical Research Associate
Organization
Advanced Circulatory

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 29, 2013

First Posted

April 5, 2013

Study Start

April 1, 2013

Primary Completion

November 1, 2016

Study Completion

November 1, 2016

Last Updated

September 27, 2017

Results First Posted

September 27, 2017

Record last verified: 2017-08

Locations